Analyst Price Targets — TECH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 12:58 pm | — | Stifel Nicolaus | $65.00 | $67.64 | TheFly | Bio-Techne price target raised to $65 from $60 at Stifel |
| February 5, 2026 12:34 pm | — | UBS | $79.00 | $68.67 | TheFly | Bio-Techne price target raised to $79 from $70 at UBS |
| February 5, 2026 12:22 pm | — | Robert W. Baird | $70.00 | $68.67 | TheFly | Bio-Techne price target raised to $70 from $61 at Baird |
| January 5, 2026 11:22 am | — | Evercore ISI | $62.00 | $59.65 | TheFly | Bio-Techne downgraded to In Line from Outperform at Evercore ISI |
| December 12, 2025 2:07 pm | Justin Bowers | Deutsche Bank | $72.00 | $59.67 | TheFly | Bio-Techne price target raised to $72 from $66 at Deutsche Bank |
| November 20, 2025 2:40 pm | — | Argus Research | $68.00 | $58.64 | TheFly | Bio-Techne price target raised to $68 from $65 at Argus |
| November 6, 2025 5:42 pm | — | Evercore ISI | $68.00 | $58.40 | TheFly | Bio-Techne price target lowered to $68 from $72 at Evercore ISI |
| September 2, 2025 8:09 pm | Conor McNamara | RBC Capital | $73.00 | $53.42 | TheFly | Bio-Techne upgraded to Outperform at RBC on forecast multiple expansion |
| March 17, 2025 8:21 pm | — | Evercore ISI | $75.00 | $62.58 | TheFly | Bio-Techne initiated with an Outperform at Evercore ISI |
| October 31, 2024 7:11 am | Catherine Schulte | Robert W. Baird | $84.00 | $76.02 | StreetInsider | Bio-Techne Corp. (TECH) PT Raised to $84 at Baird |
Latest News for TECH
Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript
American Century Companies Inc. boosted its position in Bio-Techne Corp (NASDAQ: TECH) by 78.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,037,806 shares of the biotechnology company's stock after buying an additional 894,987 shares during the
Citigroup Inc. trimmed its stake in shares of Bio-Techne Corp (NASDAQ: TECH) by 33.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 197,392 shares of the biotechnology company's stock after selling 97,843 shares during the period. Citigroup Inc. owned
CMB.TECH NV (CMBT) Q4 2025 Earnings Call Transcript
CMB.TECH ANNOUNCES Q4 2025 RESULTS EIGHT VLCCS SOLD AT STELLAR PRICES ANTWERP, Belgium, 26 February 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the fourth quarter ended 31 December 2025. HIGHLIGHTS Financial highlights: Profit for the period of USD 90.1 million in Q4 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.